Stay updated on Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now shows revision v3.3.2, replacing the previous revision v3.2.0.SummaryDifference0.0%

- Check18 days agoChange DetectedRemoved the site-wide notice about a lapse in government funding and the related operating-status guidance. The notice previously stated that information may not be up to date and directed users to cc.nih.gov and opm.gov for status updates.SummaryDifference0.2%

- Check40 days agoChange DetectedThe screenshots show the same study details page with no substantive differences in the study design, eligibility criteria, interventions, or outcomes; any differences appear to be minor or cosmetic edits that do not affect the page’s primary purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedCore content updated: a government funding and operating status notice has been added and the version updated to v3.2.0; the prior v3.1.0 tag was removed.SummaryDifference2%

- Check69 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.0%

- Check83 days agoChange DetectedExpanded to 128 locations with many new hospitals, updated to revision v3.0.2 and current dates; older 122-location data and some older entries were removed.SummaryDifference2%

Stay in the know with updates to Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tiragolumab Combo vs. Pembrolizumab in Lung Cancer Clinical Trial page.